Preclinical Evaluation of ¹⁷⁷Lu-PSMA-XT for Targeted Treatment of Prostate Cancer with Moderate PSMA Expression (EANM 2026) - Sep 29, 2026 - Abstract #EP-0178; "Aim/Introduction: Current ¹⁷⁷Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer is limited by insufficient tumor uptake, rapid clearance, and the need for high doses and repeated cycles... ¹⁷⁷Lu-PSMA-XT showed high binding affinity, improved tumor uptake, and prolonged retention, indicating therapeutic potential for prostate cancer with moderate PSMA expression."
Preclinical • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • FOLH1
|
|
Y. Liu; R. Xue; X. Zhang; B. Xu; H. Wang; R. Wang; J. Zhang
|